ADA: MannKind Has Evolved Rapidly To Accommodate Confident Afrezza Relaunch
Executive Summary
Six months ago it seemed as though the sky was falling for small drug developer MannKind, when its big pharma licensing partner, Sanofi, pulled out of their deal for the manufacture and distribution of approved inhaled insulin therapy, Afrezza. However, MannKind Corp. made rapid changes to evolve its business into a specialty pharmaceutical company and took back the drug to market on its own – a feat it had never performed before.